<DOC>
	<DOC>NCT01323946</DOC>
	<brief_summary>The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.</brief_summary>
	<brief_title>Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children</brief_title>
	<detailed_description>This protocol posting was modified according to the protocol amendment 2 (dated 16-June-2011). The impacted section is eligibility criteria.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that parents/Legally Acceptable Representatives (LARs) can and will comply with the requirements of the protocol. Children, male or female between, and including, 6 and 35 months of age at the time of first study vaccination. Written informed consent obtained from the parent(s)/LAR(s) of the subject. Healthy children as established by medical history and clinical examination before entering the study. Parent/LAR access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multipleuser device. Subjects who are likely to reside in the vicinity of the study centre for the duration of the study. In studies using the homebased model for vaccination and followup, subjects who are likely to remain in the vicinity of the area where they were recruited. Use of any investigational or nonregistered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration of immunosuppressants or other immunemodifying drugs within six months prior to the first vaccine dose. Planned administration of any vaccine 30 days prior and 21 days after any study vaccine administration. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines such as egg protein or thiomersal. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. History of any neurological disorders or seizures. Acute disease at the time of enrolment. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests. Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned administration during the study period. Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study. Child in care. Previous vaccination at any time with an H5N1 vaccine. Medical history of physicianconfirmed infection with a H5N1 virus.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>H5N1</keyword>
	<keyword>influenza infection</keyword>
	<keyword>Influenza vaccine GSK1562902A</keyword>
</DOC>